X
KEY SERVICES
Details:
SRP 3D (diethylamide) is a novel, first-in-class non-opioid analgesic that activates pain signaling pathways in the midbrain's periaqueductal grey (PAG) region without liver and kidney toxicities. It is being evaluated in phase 1 clinical trials for the treatment of acute pain.
Lead Product(s): Diethylamide
Therapeutic Area: Neurology Product Name: SRP 3D
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: South Rampart Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.
Lead Product(s): YCT-529
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: YCT-529
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
YCT-529 is a retinoic acid receptor-alpha (RAR-alpha) inhibitor that prevents sperm production by blocking access to vitamin A. It is under phase 1 clinical development for male contraception.
Lead Product(s): YCT-529
Therapeutic Area: Endocrinology Product Name: YCT-529
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: YourChoice Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 13, 2023
Details:
MIV-818 (fostroxacitabine bralpamide) is DNA inhibitor. It is being evaluated under phase 1/2 clinical development in combination with Lenvima (lenvatinib) for the treatment of hepatocellular carcinoma.
Lead Product(s): Fostroxacitabine Bralpamide,Lenvatinib
Therapeutic Area: Oncology Product Name: MIV-818
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: Medivir
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 27, 2023
Details:
EVX-101 is a novel, proprietary, gastro-retentive, sustained-release tablet formulation of 5-hydroxytryptophan (5-HTP), which is investigated for the treatment of major depressive disorder.
Lead Product(s): HSDB 4295,Carbidopa
Therapeutic Area: Psychiatry/Psychology Product Name: EVX-101
Highest Development Status: Phase IProduct Type: Small molecule
Recipient: Evecxia Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
Under the partnership, Quotient will support Crinetics' CRN04894 pediatric program. The partnership will utilize Quotient Sciences' unique Translational Pharmaceutics® platform to provide integrated formulation development, clinical manufacturing, and taste assessment studies.
Lead Product(s): CRN04894
Therapeutic Area: Endocrinology Product Name: CRN04894
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Crinetics Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 30, 2023
Details:
PF614-MPAR (oxycodone prodrug) binds and inhibits adenylyl-cyclase and hyperpolarisation of neurons, and decreased excitability, thus reduces severe pain. It is the first opioid drug product that has both abuse deterrent properties as well as overdose protection.
Lead Product(s): Oxycodone Prodrug,Nafamostat
Therapeutic Area: Neurology Product Name: PF614-MPAR
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ensysce Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2023
Details:
HTD1801 (berberine ursodeoxycholate), is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), and nonalcoholic steatohepatitis (NASH).
Lead Product(s): Berberine Ursodeoxycholate
Therapeutic Area: Endocrinology Product Name: HTD1801
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: HighTide Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 15, 2022
Details:
Under the partnership, Quotient Sciences will support the GMP manufacture and first clinical pharmacokinetic (PK) study for EMPLI03 (buprenorphine) using its unique Translational Pharmaceutics® platform for the treatment of moderate to severe pain.
Lead Product(s): Buprenorphine
Therapeutic Area: Neurology Product Name: Empli03
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Emplicure
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 29, 2022
Details:
OXL001, has been developed utilising a novel bio-enabling platform technology, it has been taken into clinical studies which gives its immense potential as a pan-cancer therapy.
Lead Product(s): OXL001
Therapeutic Area: Oncology Product Name: OXL001
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxilio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
Quotient Sciences- Molecule to Cure. Fast.
